Background
==========

Botswana has an approximate 30% seroprevalence for HIV-1 \[[@B1]\] and was also one of the first African countries to provide universal free access to antiretroviral therapy (ART) in 2002. Prior to 2002, most patients in Botswana initiated therapy with d4T/ddI-based regimens. From January 2002, the main first-line regimen in Botswana was ZDV/3TC plus either efavirenz (EFV) or nevirapine (NVP) in women in whom pregnancy was likely to occur. For patients failing initial regimens, the main second-line regimen was d4T/ddI plus nelfinavir (NFV). More recently, lopinavir/ritonavir (LPV/r) has been approved for use in second-line to replace NFV, while tenofovir (TDF)/3TC is now used as a nucleoside reverse transcriptase inhibitor (NRTI) backbone in first-line \[[@B2]\].

By March 2007, 84,927 patients had entered the national ART programme, while an additional 9,514 had been followed in the private sector. The percentage of patients receiving therapy is estimated to be greater than 80% of the total need \[[@B3]\]. As of April 2007, a total of 17,400 patients had been registered at the Adult Infectious Disease Care Clinic (IDCC) located at the Princess Marina Hospital in Gaborone. Among these, approximately 11,000 were receiving comprehensive HIV treatment and care. This site has also launched a treatment failure protocol that has ascertained the treatment failure rate among ARV patients to be 4% \[[@B4]\].

Both acquired \[[@B5]\] and transmitted \[[@B6]\] drug resistance represent obstacles for the long-term use of ARVs. Previous publications from the IDCC described the frequencies and patterns of mutations in the reverse transcriptase (RT) and protease (PR) genes \[[@B7]-[@B9]\]. In general, no major impact of HIV subtypes has been observed regarding drug susceptibility \[[@B10],[@B11]\].

We previously demonstrated that d4T/ddI-based regimens were associated with high rates of selection of the K65R mutation in HIV-1 subtype C \[[@B8],[@B12]\]. For purposes of this analysis, patients failing therapy have been divided into those who received d4T/ddI as part of their first regimen (Group 1) versus those who initiated therapy with ZDV/3TC and who received ddI as part of second or subsequent regimens (Group 2). We also attempted to delineate associations between different mutations that are involved in drug resistance, as has already been calculated in subtype B viruses \[[@B13]-[@B15]\].

Methods
=======

Patients and HIV-1 subtype C sequencing
---------------------------------------

Among the 4% of Batswana patients who experienced treatment failure at the IDCC, 363 received a ddI-based regimen as part of their first (Group 1) or second or subsequent regimen (Group 2). As recommended by the Botswana national programme since March 2005, all patients experiencing virological failure after their second-line regimen, mostly containing NFV as a first PI were evaluated by genotyping, *viz.*, a total of 63 patients (27 in Group 1 and 36 in Group 2).

These genotypes were linked to patients\' demographic, immunologic, virologic and therapeutic clinical data. HIV genotyping for drug resistance was performed on plasma samples using a commercially available kit (ViroSeq HIV-1 genotyping system; Abbott Laboratories). All the patients were confirmed as possessing subtype C viruses on the basis of nucleotide sequence alignment using the ClustalX-version 1.8 sequencing tool \[[@B16]\]. The neighbour-joining method was employed for phylogenetic tree building using the NJplot programme.

Statistical and mutational covariate analysis
---------------------------------------------

We first calculated the frequencies of RT and PR mutations in the *pol*sequences of 26 Group 1 and 37 Group 2 patients who were followed. We also established relationships between the presence of specific mutations using both the Pearson correlation coefficient (P) and the Jaccard similarity coefficient (J). A Fisher\'s exact test was also performed to assess the significance of any associations that were found. As a reference, we employed the 2008 IAS-USA list of mutations \[[@B17]\].

Results
=======

Patient characteristics
-----------------------

The characteristics of the 63 patients followed in this study are shown in Table [1](#T1){ref-type="table"}, with virologic failure being defined as the inability to suppress plasma viremia or the rebound of viral load (VL) on at least two consecutive occasions to levels \>400 copies RNA/ml. Median CD4 cell counts at failure were 334 cells/mm^3^for Group 1 and 233 cells/mm^3^for Group 2 and medians of viral loads (log10 HIV-1 RNA copies/ml) were 4.2 and 4.7 for Group 1 and 2, respectively, at which time most patients had received three different treatment regimens.

###### 

Characteristics of the 63 patients who received ddI/d4T (Group 1) versus ZDV/3TC (Group 2) as first-line therapy

  --------------------------------------------------------------------------------------------------------------------------------
                                                                                                      Group 1\       Group 2\
                                                                                                      (n = 26)       (n = 37)
  --------------------------------------------------------------------------------------------------- -------------- -------------
  *Age (years)*\                                                                                      35\            34\
  Median\                                                                                             \[24-57\]      \[21-48\]
  Interquartile range                                                                                                

                                                                                                                     

  *Female sex (%)*                                                                                    61.5           60.7

                                                                                                                     

  *Baseline nadir CD4 cell count*\                                                                    96 \[2-276\]   61\
  Median\                                                                                                            \[1-317\]
  Interquartile range                                                                                                

                                                                                                                     

  *CD4 cell count at failure visit*\                                                                  334\           233\
  Median\                                                                                             \[41-937\]     \[9-1313\]
  Interquartile range                                                                                                

                                                                                                                     

  *Log10 HIV-1 RNA at failure visit*\                                                                 4.2\           4.7\
  Median\                                                                                             \[2.9-5.33\]   \[3.5-5.9\]
  Interquartile range                                                                                                

                                                                                                                     

  *Total days on antiretroviral therapy at the time of genotype*\                                     998\           486\
  Median Interquartile range                                                                          \[228-2507\]   \[59-1346\]

                                                                                                                     

  *Total time (days) to non-detectability of viral load (\<400 copies/ml) at the time of genotype*\   158\           96\
  Median\                                                                                             \[28-1693\]    \[10-1188\]
  Interquartile range                                                                                                

                                                                                                                     

  *Average number of ARV regimens received by the time of genotype*                                   3\*            2.5^†^
  --------------------------------------------------------------------------------------------------------------------------------

\*Group 1 - ARV regimens received by the time of genotyping. [ddI/d4T/NVP]{.ul}, ZDV/3TC/EFV, ddI/d4T/NFV; [ddI/d4T/NVP]{.ul}, ZDV/3TC/NVP, d4T/3TC/NVP, ABC/ddI/NFV; [ddI]{.ul}, ddI/d4T/NVP; [ddI/ZDV]{.ul}, ddI/d4T/EFV, ZDV/3TC/NFV; [ddI/ZDV/3TC]{.ul}, ZDV/3TC/NVP, ABC/ddI/NFV; [ddI/d4T/EFV]{.ul}, ZDV/3TC/EFV, ddI/d4T/NFV; [ddI/d4T/NVP]{.ul}, ZDV/3TC/NFV (n = 2); [ddI/d4T]{.ul}, ZDV/3TC/NVP, ddI/TDF/LPVr; [ddI/d4T/EFV]{.ul}, ZDV/3TC/EFV (n = 3); [ddI/ZDV]{.ul}, ZDV/3TC/NVP, ddI/d4T/NFV; [ddI/d4T/NVP]{.ul}, ZDV/3TC/NFV, LPVr/SQV; [ddI/ZDV/NVP]{.ul}, 3TC/d4T/NFV; [ddI/d4T]{.ul}, ZDV/3TC/EFV, ddI/d4T/SQV/RTV; [ddI/d4T/NVP]{.ul}, ZDV/3TC/NFV, ZDV/TDF/LPVr; [ddI/ZDV/NVP]{.ul}, 3TC/d4T/IDV/RTV; [ddI/d4T/EFV]{.ul}, ddI/d4T/NFV; [ddI/d4T]{.ul}, ddI/d4T/NVP, ZDV/3TC/EFV; [ddI/d4T/NVP]{.ul}, ZDV/3TC/NVP; [ddI/d4T]{.ul}, 3TC/ddI, ZDV/3TC/NVP, ZDV/3TC/EFV; [ddI/d4T]{.ul}, ZDV/3TC/SQV/RTV, ZDV/3TC/NVP; [ddI/d4T/EFV]{.ul}, ZDV/3TC/EFV, ABC/ddI/NFV, ddI/d4T/EFV/LPV; [ddI/d4T/EFV]{.ul}, ABC/ddI/NFV, d4T/3TC/EFV; [ddI/ZDV/NVP]{.ul}, d4T/3TC/IDV, ddI/d4T/NFV.

^†^Group 2 - ARV regimens received by the time of genotyping. [ZDV/3TC/NVP]{.ul}; [ZDV/3TC/NVP]{.ul}, ddI/d4T/NVP, ZDV/3TC/NVP, 3TC/ddI/NFV, 3TC/ABC/ddI/LPV; [ZDV/3TC/NVP]{.ul}, ddI/d4T/NFV (n = 13); [ZDV/SQV/RTV]{.ul}, ddI/d4T, ddI/d4T/NFV, 3TC/ABC/LPV; [ZDV/3TC/EFV]{.ul}, ddI/TDF/LPV; [ZDV/3TC/IDV]{.ul}, ZDV/3TC/NVP, ddI/d4T/NVP; [ABC/ddI/NVP]{.ul}; [3TC/d4T/NVP]{.ul}, ZDV/ddI/NFV; [ZDV/3TC/NVP]{.ul}, ddI/d4T/NFV, ZDV/3TC/LPV; [ZDV/3TC/EFV]{.ul}, ddI/d4T/NFV (n = 5); [ZDV/3TC/NVP]{.ul}, ddI/d4T/NFV, ABC/SQV/RTV; [ZDV/3TC/NVP]{.ul}, ddI/d4T/NFV, ABC/ddI/NFV; [ZDV/3TC]{.ul}, SQV/RTV, ddI/d4T/SQV/RTV, ABC/d4T/ddI/LPV, 3TC/ddI/EFV; [3TC/d4T/EFV]{.ul}, ZDV/3TC/NFV; [3TC/d4T/EFV (n = 2)]{.ul}; [ZDV/3TC/EFV]{.ul}, 3TC/d4T/NVP; [ZDV/3TC/EFV]{.ul}, ABC/ddI/NFV; [ZDV/3TC/EFV]{.ul}(n = 2); [ZDV/3TC]{.ul}, IDV/NVP, 3TC/ABC/d4T, d4T/EFV/IDV/RTV, 3TC/ABC/d4T, 3TC/ABC/d4T/LPV, 3TC/ABC/AZT/LPV.

Mutations to protease inhibitors
--------------------------------

Phylogenetic analysis indicated that all of the 63 patients who were genotyped possessed subtype C viruses. Approximately 78% of PI-treated individuals exhibited resistance mutations; similar patterns of resistance were observed among both groups (Figure [1](#F1){ref-type="fig"}). Among patients who received NFV, the most common mutations observed were D30N and L90M, consistent with previous results (Table [2](#T2){ref-type="table"}).

![**Frequency of HIV-1 subtype C protease mutations**. **A**- The frequency of amino acid mutations in HIV-1 subtype C (white) or B (black) protease in drug-naïve patients are reported based on the Stanford HIV drug resistance database. **B**- Amino acids in HIV-1 subtype C protease of Batswana treated patients from Group 1 (white) or Group 2 (black) are reported. Where more than one amino acid change may have occurred, the most prevalent amino acid is underlined.](1758-2652-12-25-1){#F1}

###### 

Frequency of mutations within PR

  Mutations    Frequency (%)   *\*P*value    
  ------------ --------------- ------------- ------
               **Group 1**     **Group 2**   
                                             
  L10F/I       23              37            0.23
                                             
  K20R/T/I/M   34.6            60            0.07
                                             
  D30N         19.2            25.7          0.43
                                             
  E35D/N       50              60            0.31
                                             
  K45Q         3.8             17.14         0.12
                                             
  M46I         7.7             20            0.19
                                             
  D60E         23              34.28         0.43
                                             
  Q61E/D       19              42.8          0.06
                                             
  I62V         0               11.4          0.11
                                             
  N88D         11.5            8.6           0.48
                                             
  N88S         7.7             11.4          0.51
                                             
  L89M         57.7            57.1          0.51
                                             
  L89I         19.2            14.3          0.39
                                             
  L90M         15              28            0.34

\**P*value: probability of significant differences between groups

Interestingly, 43% of patients possessed a Q61E mutation (CAA → GAA) that emerges from a silent substitution, i.e., CAA in subtype C relative to CAG in subtype B. The I62V resistance mutation was present in 11% of those patients who only received NFV as a PI. We confirmed the correlation seen by others between D30N and N88D (P = 74 and 52.4, J = 60 and 33.3; *p*= 0.004 and 0.01 for Groups 1 and 2, respectively) and also observed a novel association between D30N and K45Q (P = 60, J = 50; *p*= 0.002; Group 2), while L89I was only found in association with D30N (P = 50.5, J = 50; *p*= 0.002; Group 2) (Table [3](#T3){ref-type="table"}).

###### 

Significant correlations of pairs of mutations within PR

  Mutations    Correlated mutations   Pearson coeff.   Jaccard coeff.   *P*value (freq cell)                                               
  ------------ ---------------------- ---------------- ---------------- ---------------------- ------------- ------------- --------------- --------------
               **Group 1**            **Group 2**      **Group 1**      **Group 2**            **Group 1**   **Group 2**   **Group 1**     **Group 2**
                                                                                                                                           
  L10F/I       K20R/T/I/M             M46I             36.9             36.7                   36.4          33.3          0.13 (15.4)     0.07 (13.5)
               D30N                   A71V             42.8             37.1                   37.5          28.5          0.06 (11.5)     0.04 (10.8)
               Q61E/D                                  42.8                                    37.5                        0.06 (11.5)     
               T74S                   T74S             65.9             44.4                   57.1          43.7          0.005 (15.4)    0.02 (0.02)
               N88D                   N88D             65.9             40.36                  50            23            0.008 (11.5)    0.04 (8.1)
               N88S                                    52                                      33                          0.05 (7.7)      
                                                                                                                                           
  K20R/T/I/M   E35D/N                 E35D/N           40.4             50.1                   46.7          65.4          0.10 (26.9)     0.006 (45.9)
               M46I                   K45Q             39.7             38.4                   0             28.5          0.11 (7.7)      0.03 (16.2)
               T74S                                    46.5                                                                0.03 (15.4)     
               V77I                                    39.7                                                                0.11 (7.7)      
               N88S                                    39.7                                                                0.11 (7.7)      
                                                                                                                                           
  D30N         K45Q                   K45Q             41               60.5                   20            50            0.19 (3.85)     0.002 (13.5)
               N88D                   N88D             74               52.4                   60            33.3          0.004 (11.5)    0.01 (8.1)
               L89I                                    50.5                                    42.8                        0.03 (11.5)     
                                                                                                                                           
  E35D/N       T74S                                    48.8                                    38.5                        0.04 (19.2)     
                                                                                                                                           
  M46I                                A71V                              41.5                                 33.3          0.04 (8.1)      
                                      V77I                              41.5                                 33.3          0.04 (8.1)      
                                                                                                                                           
  D60E                                Q61E/D                            48.6                                 50            0.005 (24.32)   
                                                                                                                                           
  Q61E/D       N88S                                    59                                      40                          0.03 (7.7)      

Mutations to reverse transcriptase inhibitors
---------------------------------------------

Approximately 87% of the patients who were genotyped possessed mutations associated with resistance to NNRTIs, while 90% presented with mutations associated with NRTIs (Table [4](#T4){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). Some individuals in Group 2 possessed I202V, L228R/H and D324E substitutions. M184V was observed in 16 of 26 Group 1 patients, 14 of whom had received 3TC prior to genotyping. In patients from Groups 1 and 2, both TAM 1 (48%) and TAM 2 (59%) mutations were present.

![**Frequency of HIV-1 subtype C reverse transcriptase mutations**. **A**- The frequency of amino acid mutations in HIV-1 subtype C (white) or B (black) reverse transcriptase in drug-naïve patients are reported based on the Stanford HIV drug resistance database. **B**- Amino acids in HIV-1 subtype C reverse transcriptase of Batswana treated patients from Group 1 (white) or Group 2 (black) are reported. Where more than one amino acid change may have occurred, the most prevalent amino acid is underlined.](1758-2652-12-25-2){#F2}

###### 

Frequency of mutations within RT.

  Mutations            Frequency (%)   *\*P*value    
  -------------------- --------------- ------------- -------
                       **Group 1**     **Group 2**   
                                                     
  **NNRTI**                                          
                                                     
  A98S/G               26.9            18.9          \-
                                                     
  K101E/Q/P/R          19.23           21.6          \-
                                                     
  K103N                34.6            48.6          \-
                                                     
  V106M                30.8            16.21         \-
                                                     
  V108I                15.4            18.9          \-
                                                     
  E138A                15.4            27            \-
                                                     
  V179E/D              15.3            13.5          \-
                                                     
  Y181C                23              27            \-
                                                     
  Y188L                0               13.5          \-
                                                     
  G190A                23              13.5          \-
                                                     
  **NRTI (non-TAM)**                                 
                                                     
  K65R                 7.7             0             \-
                                                     
  S68G                 19.2            8.1           \-
                                                     
  L74V/I               7.7             16.2          \-
                                                     
  Q151M                3.8             2.7           \-
                                                     
  M184V                61              40.5          \-
                                                     
  **TAM1**                                           
                                                     
  41L                  26.9            40.5          \-
                                                     
  210W                 19.2            18.9          \-
                                                     
  215Y                 26.9            29.7          \-
                                                     
  **TAM2**                                           
                                                     
  67N                  46              67.56         0.07
                                                     
  70R                  35              37.8          \-
                                                     
  215F                 26.9            29.7          \-
                                                     
  219Q                 34.6            37.8          \-
                                                     
  **Others**                                         
                                                     
  E53D                 11.5            13.5          \-
                                                     
  K102R/Q/N            15.4            0             \-
                                                     
  I135V/T              30.8            45.9          \-
                                                     
  T139A/P/S            0               16.2          \-
                                                     
  I142V/T              15.4            8.1           \-
                                                     
  A158S                23              0             \-
                                                     
  S162C/A/T            15.4            24.3          \-
                                                     
  I178L/M              19              35            \-
                                                     
  I202V                34.6            8             0.008
                                                     
  E203A/K/D            3.8             18.9          \-
                                                     
  H221Y                11.5            18.9          \-
                                                     
  L228R/H              8               27            0.05
                                                     
  D250E                42.3            40.5          \-
                                                     
  K275R/Q              23              8             0.09
                                                     
  D324E                27              8             0.04

\**P*value: probability of significant differences between groups

Similarly, 10 of 15 Group 2 patients who possessed M184V had been on a 3TC-containing regimen at the time of testing. Only two patients carried the K65R mutation; one of these had received TDF and the other had received ddI at the time of genotyping. The length of time on ineffective regimens (based on non-suppressed VL) was 809 days and 279 days for Groups 1 and 2, respectively.

Patients with the L74V mutation (16.2% in Group 2) were on ABC/ddI at the time of genotyping. In the group of patients who received EFV, the most frequent mutations were K103N, V106M and I135V/T, while Y181C and G190A were more frequent among patients who received NVP. In Group 2 patients, the Y181C and A98S/G mutations were found in association with the L228R/H mutation, \[(J = 66.6, *p*= 0.0001) and (J = 41.7, *p*= 0.009), respectively\], while L228R/H was associated with G190A in Group 1 patients (Table [5](#T5){ref-type="table"}). We also observed an association between H221Y and Y181C in Group 1 patients treated with NVP.

###### 

Significant correlations of pairs of mutations within RT.

  Group 1      Pearson coeff.   Jaccard coeff.   *P*value   Group 2      Pearson coeff.   Jaccard coeff.   *P*value
  ------------ ---------------- ---------------- ---------- ------------ ---------------- ---------------- ----------
  101E/190A    65.92            57.1             0.005      101E/190A    36.8             30               0.06
  101E/219Q    46.55            40               0.034      106M/139A    40.32            33.3             0.04
  102R/53D     51.3             40               0.05       106M/138A    39.3             33.3             0.04
  103N/178L    46               40               0.03       106M/179E    46.9             37.5             0.02
  106M/283I    63.9             50               0.005      108I/208Y    49.85            37.5             0.02
  190A/69D     65.9             50               0.008      181C/67N     42.2             40               0.01
                                                            181C/69D     64.9             50               0.001
                                                            181C/98S     63.8             54.5             0.001
  142V/158S    52.5             42.8             0.03       181C/228R    72.6             66.6             0.0001
  178L/135V    52.5             44.4             0.02                                                      
  221Y/162C    51.3             40               0.05       190A/41L     47.9             33.3             0.007
  221Y/181C    66               50               0.008      190A/210W    41.5             33.3             0.04
  228R/190A    52.7             33.3             0.05       190A/215Y    43.5             33.3             0.02
  251D/53D     58.4             60               0.004      190A/74L     46.9             37.5             0.02
  278N/60I     62.3             50               0.03                                                      
  283I/102R    70.4             60               0.006      228R/98S     48               41.7             0.009
  294T/102R    67.7             50               0.02       228R/215F    40               40               0.04
                                                            210W/215Y    44.07            38.4             *ND*
                                                                                                           
  210W/215Y    36.4             33.3             *ND*       41L/215Y     42.64            44.4             *ND*
  41L/215Y     41.3             40               *ND*       41L/210W     44.4             37.5             *ND*
  41L/210W     36.4             33.3             *ND*       41L/53D      31.7             25               *ND*
  41L/53D      59.5             42.8             *ND*       41L/74V/I    53               40               *ND*
  67N/70R      62.37            61.5             *ND*       67N/70R      54.05            56               *ND*
  70R/219Q     83.01            80               *ND*       70R/219Q     65.53            64.7             *ND*
  219Q/67D     62.37            61.5             *ND*       219Q/67D     54.05            56               *ND*
  215F/67D     40.85            35.7             *ND*       215F/67D     45.06            44               *ND*
  215F/70R     36.9             33.3             *ND*       215F/70R     34.6             38.9             *ND*
  219Q/69N/D   49.64            33.3             *ND*       219Q/69N/D   34.36            27               *ND*

Discussion
==========

This study provides data on drug resistance mutational profiles in HIV-1 subtype C-infected Batswana patients who experienced treatment failure between 2002 and 2007. Among novel findings, we have shown that resistance to NFV in these patients seems to involve the K45Q mutation in association with D30N, and occurs with similar frequency (J = 50, *p*= 0.002) as that previously characterized between D30N and N88D (J = 33.3, *p*= 0.01). The L89I mutation was also associated with D30N, suggesting that it may occur early in the establishment of resistance to NFV. Accumulation of large numbers of PI mutations may reflect the duration of time that patients may have been left on a failing regimen \[[@B18]\].

We previously demonstrated a greater propensity for patients infected by HIV-1 subtype C to develop the K65R mutation after treatment with ddI-based regimens in first-line therapy \[[@B8]\]. More recently, high rates of K65R were also observed among patients from West Africa who received 3TC/d4T/NNRTI as a first-line regimen \[[@B19],[@B20]\]. High rates of virologic failure have also been reported in patients with the K65R mutation compared to L74V \[[@B21],[@B22]\]. Both the L74V and K65R mutations may impact on subsequent TDF responses in patients who had previously received ddI \[[@B22]\].

Clearly, these two nucleoside cross-resistance mutations may compromise a wide array of future nucleoside-based therapeutic options in treatment-experienced patients. In the present study, the frequency of the K65R mutation was low (two of 26 patients). One possible explanation may be the reversion of the K65R mutation after use of subsequent ARV regimens, due to considerations of low viral fitness. This phenomenon emphasizes the need for more sensitive assays that can be used for surveillance of resistance mutations.

The high frequency of NNRTI mutations is also disturbing and raises questions about their use in first-line regimens in developing countries, where financial constraints may often compel physicians to keep patients on failing regimens for longer than desirable. In this context, it might be interesting to conduct a study such as ACTG 5142 \[[@B23]\], which compared the use of EFV to a first-line PI, in settings where subtype C viruses are predominant.

We also observed several associations involving less common resistance mutations, such as L228R/H and Y181C (J = 66.6, *p*= 0.0001) and A98S/G (J = 41.7, *p*= 0.009) in Group 2 patients and L228R/H in association with G190A in Group 1. We further observed a preferential emergence of the H221Y mutation in Group1 NVP-treated patients, who first exhibited the Y181C mutation. Moreover, mutations at positions A98, K101, V106, E138, Y181 and G190 were discovered, and it is not yet known whether these substitutions will affect clinical responsiveness to new NNRTIs, such as etravirine (ETV), in HIV-1 subtype C infections \[[@B24]\]. A review article on the subject of HIV drug resistance mutations and viral subtypes has recently been published \[[@B25]\].

Switching from ZDV/3TC to d4T/ddI (Group 2) and subsequent maintenance on a suboptimal NVP-containing regimen may also have resulted in higher rates of association between G190A and TAMs or G190A and L74V. Others have shown the co-presence of L74V and Y181C in patients who failed a NVP-containing regimen \[[@B26]\].

Although the Botswana ARV national programme has tried to optimize ARV therapy and has changed first- and second-line regimens to TDF/FTC/NNRTI and ZT/3TC/LPV/r, respectively, our results remain relevant for other developing country settings that still use ineffective combinations in a context of poor adherence. Indeed, it is important to understand genotypic resistance patterns in developing countries where treatment options may be more limited than those that are available wealthier countries and in which different viral subtypes may predominate. Associations such as those between the D30N and K45Q mutations in PR have not previously been reported. It is likely that the use of suboptimal therapy may facilitate the emergence of novel resistance pathways and that this will become a major concern in resource-limited settings.

Conclusion
==========

HIV subtype C-infected patients in Botswana who began therapy with either d4T/ddI- or ZDV/3TC-based regimens and who failed therapy have developed drug resistance-associated mutations at high frequency. These mutations are associated with resistance against each of NRTIs, NNRTIs, and PIs and include several novel substitutions relative to those typically observed with subtype B viruses. Hopefully, the current use of improved treatment regimens in Botswana will mitigate both rates of treatment failure as well as the future development and transmission of HIV.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

FDB wrote the initial draft of this manuscript and was largely responsible for compilation and interpretation of results. TG and AA helped draft the paper and manage data. SC and CH contributed data to the paper, while NN, HM, and ME corrected the paper and provided supervision. MM directed the laboratory in which sequencing results were obtained. MAW corrected the manuscript, provided interpretation of data, and collated results.

Acknowledgements
================

We thank the Botswana Ministry of Health for encouragement (study approved by the National Health Research Development Committee of the Botswana Ministry of Health), Mpho Zwinila for database management, and the Service of Infectious Diseases at the IDCC, Princess Marina Hospital, Gaborone, Botswana, for its contribution to this work. This study was funded by grants from the Secure the Future programme of Bristol-Myers-Squibb, Inc, the National Institutes of Health (USA) and the Canadian Institutes of Health Research.
